{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:43:19Z","timestamp":1789699399753,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Psychiatry"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/s2215-0366(17)30331-0","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T23:00:24Z","timestamp":1505862024000},"page":"859-867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies"],"prefix":"10.1016","volume":"4","author":[{"given":"Myrto T","family":"Samara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Z","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2215-0366(17)30331-0_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib2","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/S2215-0366(17)30331-0_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis","volume":"303","author":"Fournier","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/S2215-0366(17)30331-0_bib4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archgenpsychiatry.2011.2044","article-title":"Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine","volume":"69","author":"Gibbons","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1192\/bjp.bp.115.173906","article-title":"Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials","volume":"209","author":"Rabinowitz","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib6","author":"Hyman"},{"key":"10.1016\/S2215-0366(17)30331-0_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","article-title":"Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies","volume":"72","author":"Furukawa","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","article-title":"Initial severity and efficacy of risperidone in autism: results from the RUPP trial","volume":"32","author":"Levine","year":"2016","journal-title":"Eur Psychiatry"},{"issue":"suppl 1","key":"10.1016\/S2215-0366(17)30331-0_bib9","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jad.2007.02.007","article-title":"Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms","volume":"100","author":"McIntyre","year":"2007","journal-title":"J Affect Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2007.08.015","article-title":"Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder","volume":"107","author":"Suppes","year":"2008","journal-title":"J Affect Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1017\/S1461145710001641","article-title":"Factors modifying drug and placebo responses in randomized trials for bipolar mania","volume":"14","author":"Yildiz","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/0004867415614109","article-title":"Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: network meta-analysis","volume":"49","author":"Glue","year":"2015","journal-title":"Aust NZ J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"key":"10.1016\/S2215-0366(17)30331-0_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib17","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4088\/JCP.v69n1113","article-title":"Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study","volume":"69","author":"Tohen","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jad.2011.10.045","article-title":"Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study","volume":"136","author":"Katagiri","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib20","series-title":"Statistical power analysis in the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/S2215-0366(17)30331-0_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mpr.1379","article-title":"Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort","volume":"22","author":"Lukasiewicz","year":"2013","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/S2215-0366(17)30331-0_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4088\/JCP.v68n0807","article-title":"A systematic review of placebo response in studies of bipolar mania","volume":"68","author":"Sysko","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib23","series-title":"Longitudinal data analysis","author":"Hedeker","year":"2006"},{"key":"10.1016\/S2215-0366(17)30331-0_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann Stat"},{"key":"10.1016\/S2215-0366(17)30331-0_bib25","series-title":"nlme: Linear and nonliniear mixed effects models. R package version 3.1-117","author":"Pinheiro","year":"2014"},{"key":"10.1016\/S2215-0366(17)30331-0_bib26","unstructured":"Canty A, Ripley B. boot: Bootstrap R (S-Plus) functions. R package version 1.3-7. 2012."},{"key":"10.1016\/S2215-0366(17)30331-0_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2307\/2087176","article-title":"Ecological correlations and the behavior of individuals","volume":"15","author":"Robinson","year":"1950","journal-title":"Am Sociol Rev"},{"key":"10.1016\/S2215-0366(17)30331-0_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.jcp.0000145342.38170.7f","article-title":"Predictors of response to treatment of acute bipolar manic episodes with divalproex sodium or placebo in 2 randomized, controlled, parallel-group trials","volume":"24","author":"Welge","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S0033291714001305","article-title":"A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania","volume":"45","author":"Yildiz","year":"2015","journal-title":"Psychol Med"},{"key":"10.1016\/S2215-0366(17)30331-0_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S2215-0366(17)30331-0_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1399-5618.2011.00904.x","article-title":"Study design and patient characteristics and outcome in acute mania clinical trials","volume":"13","author":"Tarr","year":"2011","journal-title":"Bipolar Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00005053-195701000-00009","article-title":"The law of initial value in neurology and psychiatry; facts and problems","volume":"125","author":"Wilder","year":"1957","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/S2215-0366(17)30331-0_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fpubh.2013.00029","article-title":"Assessing the relationship between the baseline value of a continuous variable and subsequent change over time","volume":"1","author":"Chiolero","year":"2013","journal-title":"Front Public Health"},{"issue":"suppl 1","key":"10.1016\/S2215-0366(17)30331-0_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1399-5618.4.s1.27.x","article-title":"Limits of the applicability and generalizability of drug trials in mania","volume":"4","author":"Licht","year":"2002","journal-title":"Bipolar Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4088\/JCP.12m07935","article-title":"Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"74","author":"Hoertel","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jad.2014.01.008","article-title":"Mixed state discrimination: a DSM problem that won't go away?","volume":"158","author":"Malhi","year":"2014","journal-title":"J Affect Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib38","first-page":"121","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm","volume":"20","author":"Fountoulakis","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bdi.12025","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013","volume":"15","author":"Yatham","year":"2013","journal-title":"Bipolar Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib40","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1176\/appi.ajp.162.7.1281","article-title":"Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial","volume":"162","author":"Tohen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1461145713001168","article-title":"Antipsychotic switching in bipolar disorders: a systematic review","volume":"17","author":"Grande","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jpsychires.2004.06.005","article-title":"Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials","volume":"39","author":"Khan","year":"2005","journal-title":"J Psychiatr Res"},{"key":"10.1016\/S2215-0366(17)30331-0_bib43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory Apologia\u2014a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants","volume":"18","author":"Melander","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00004714-200202000-00007","article-title":"Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database","volume":"22","author":"Khan","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S2215-0366(17)30331-0_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jad.2015.03.062","article-title":"Moderation of antidepressant and placebo outcomes by baseline severity in late-life depression: a systematic review and meta-analysis","volume":"181","author":"Locher","year":"2015","journal-title":"J Affect Disord"},{"key":"10.1016\/S2215-0366(17)30331-0_bib46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1176\/appi.ajp.2012.12070927","article-title":"Moderators of outcome in late-life depression: a patient-level meta-analysis","volume":"170","author":"Nelson","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(17)30331-0_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamapsychiatry.2014.112","article-title":"Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses","volume":"71","author":"Huhn","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"suppl 2","key":"10.1016\/S2215-0366(17)30331-0_bib48","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","article-title":"Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis","volume":"137","author":"Fung","year":"2016","journal-title":"Pediatrics"}],"container-title":["The Lancet Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036617303310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036617303310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:13:45Z","timestamp":1762409625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215036617303310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2215036617303310"],"URL":"https:\/\/doi.org\/10.1016\/s2215-0366(17)30331-0","relation":{},"ISSN":["2215-0366"],"issn-type":[{"value":"2215-0366","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies","name":"articletitle","label":"Article Title"},{"value":"The Lancet Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(17)30331-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(17)30370-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}